Search

Your search keyword '"Takehara, Kazuhiro"' showing total 382 results

Search Constraints

Start Over You searched for: Author "Takehara, Kazuhiro" Remove constraint Author: "Takehara, Kazuhiro" Search Limiters Academic (Peer-Reviewed) Journals Remove constraint Search Limiters: Academic (Peer-Reviewed) Journals
382 results on '"Takehara, Kazuhiro"'

Search Results

1. Re-administration of platinum-based chemotherapy for recurrent endometrial cancer: an ancillary analysis of the SGSG-012/GOTIC-004/Intergroup study

3. Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial

6. Clinical characteristics and prognostic factors of endometrial stromal sarcoma and undifferentiated uterine sarcoma confirmed by central pathologic review: A multi-institutional retrospective study from the Japanese Clinical Oncology Group

8. Prognostic impact of the number of resected pelvic nodes in endometrial cancer: Japanese Gynecologic Oncology Group Study JGOG2043 post hoc analysis

9. Neoadjuvant combination treatment of olaparib and pembrolizumab for patients with HRD-positive advanced ovarian cancer.

11. Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer.

13. Uterine serous carcinoma

14. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

19. Japan Society of Gynecologic Oncology 2022 guidelines for uterine cervical neoplasm treatment

21. PR037/#494 Pre-treatment systemic inflammatory markers predict survival in endometrial cancer: a Japanese gynaecologic oncology group (JGOG) 2043 exploratory data analysis

22. EP135/#104 The prognostic significance of the number of resected pelvic nodes in endometrial cancer: Japanese gynecologic oncology group study JGOG2043 post HOC analysis

23. EP152/#356 The prognostic significance of para-aortic lymph node metastases in endometrial cancer: Japanese gynecologic oncology group study JGOG2043 post HOC analysis

25. The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology Group study (JGOG3016A1)

26. Analysis of gastric-type mucinous carcinoma of the uterine cervix — An aggressive tumor with a poor prognosis: A multi-institutional study

27. Gestational choriocarcinoma

28. #215 Retrospective re-evaluation of platinum-free interval and chemotherapeutic effect against subsequent platinum-containing chemotherapy in recurrent ovarian cancer patients initially treated by chemotherapy with bevacizumab

31. Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2–Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial

32. Human papillomavirus vaccine impact on invasive cervical cancer in Japan: Preliminary results from cancer statistics and the MINT study.

34. Intraperitoneal Carboplatin for Ovarian Cancer — A Phase 2/3 Trial

35. Poor Treatment Outcomes of Locally Advanced Cervical Adenocarcinoma of Human Papilloma Virus Independent Type, Represented by Gastric Type Adenocarcinoma: A Multi-Center Retrospective Study (Sankai Gynecology Study Group)

36. Endometrial carcinosarcoma

37. Endometrial carcinosarcoma

38. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602

41. Clinical tumor diameter and prognosis of patients with FIGO stage IB1 cervical cancer (JCOG0806-A)

42. Endometrial carcinosarcoma

43. EP086/#167 Potential superiority of radical hysterectomy over radiotherapy in locally advanced non-squamous cell carcinoma of the cervix but not gastric-type adenocarcinoma (sankai gynecologic study group)

46. 2022-RA-680-ESGO Safety and efficacy of MORAb-202 in patients with platinum-resistant ovarian cancer: results from the expansion part of a phase 1 trial in Japan

47. A randomized phase 3 trial of intraperitoneal versus intravenous carboplatin with dose-dense weekly paclitaxel in patients with ovarian, fallopian tube, or primary peritoneal carcinoma (a GOTIC-001/JGOG-3019/GCIG, iPocc Trial) (LBA 3)

48. Multicenter observational study on optimal regimen of neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, and peritoneal cancer (328)

Catalog

Books, media, physical & digital resources